The Relationship Between Hypertension and Mortality in COVID-19 Patients at Soedirman M. S. Wonogiri Hospital

Authors

  • Devisda Shafiy Anisa Faculty of Medicine, University of Jember, Jember, Indonesia
  • Desie Dwi Wisudanti Department of Pharmacology, Faculty of Medicine, University of Jember, Jember, Indonesia https://orcid.org/0000-0002-1636-7734
  • Pipiet Wulandari Department of Physiology, Faculty of Medicine, University of Jember; Department of Cardiology, dr. Soebandi General Hospital, Faculty of Medicine, University of Jember, Jember, Indonesia

DOI:

https://doi.org/10.22225/wmj.10.2.12434.80-87

Keywords:

blood pressure, mortality, SARS-CoV-2

Abstract

According to data from the Ministry of Health of the Republic of Indonesia, there were 6,103,533 confirmed positive cases of COVID-19, with 156,776 deaths. One factor contributing to the high mortality rate of COVID-19 is the presence of comorbidities. Hypertension and diabetes mellitus are the most common comorbidities found in COVID-19 patients. In cases of hypertension, the SARS-CoV-2 virus can interfere with blood pressure regulation, resulting in sustained increases in blood pressure in infected patients. If this condition is not managed, organ damage may occur and worsen the patient’s clinical status. This study aims to evaluate the effect of comorbid hypertension on the mortality of COVID-19 patients at dr. Soediran M. S. Wonogiri Hospital. This research employed an analytical observational method with a cross-sectional design. Medical record data from 94 COVID-19 patients, consisting of 47 patients with hypertension and 47 patients without hypertension, were analyzed using the Chi-square test. The highest age distribution among COVID-19 patients was in the 51–60-year age group (21.3%). The results showed a significant association between comorbid hypertension and mortality in COVID-19 patients (p = 0.001), with an RR value of 1.27. COVID-19 patients with comorbid hypertension were 1.27 times more likely to die than those without hypertension. This study provides a better understanding of health risks in COVID-19 patients with comorbid hypertension and may assist in developing more effective health policies.

References

1. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020;24:91-98.

2. Kementerian Kesehatan RI. Situasi Terkini Perkembangan Coronavirus Disease (COVID-19) 1 September 2021. Available from: https://infeksiemerging.kemkes.go.id/situasi-infeksi-emerging/situasi-terkini-perkembangan-coronavirus-disease-covid-19-1-september-2021

3. Emami A, Javanmardi F, Pirbonyeh N, Akbari A. Prevalence of underlying diseases in hospitalized patients with COVID-19: A systematic review and meta-analysis. Arch Acad Emerg Med. 2020;8(1):e35. Available from: https://pmc/articles/PMC7096724/

4. Phyu K, Hla SA, Lin Maun N, Ni Z, Aung H, Aung SM, et al. The prevalence, clinical characteristics, predicting factors and impact of long COVID syndrome following third wave of epidemic in Myanmar: Prospective study. Int J Med Sci Clin Res Stud. 2022;2(6):461-468. Available from: https://ijmscr.org/index.php/ijmscrs/article/view/199

5. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Available from: https://doi.org/10.1183/13993003.00547-2020

6. Hikmawati I, Setiyabudi R. Hipertensi dan diabetes melitus sebagai penyakit penyerta utama COVID-19 di Indonesia. Prosiding Seminar Nasional LPPM UMP. 2020;0(0):95-100. Available from: https://semnaslppm.ump.ac.id/index.php/semnaslppm/article/view/224

7. Wu Z, McGoogan JM. Characteristics of and important lessons from the COVID-19 outbreak in China. JAMA. 2020;323(13):1239-1242. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130

8. Jamison DA, Anand Narayanan S, Trovão NS, Guarnieri JW, Topper MJ, Moraes-Vieira PM, et al. A comprehensive SARS-CoV-2 and COVID-19 review: Part 1. Eur J Hum Genet. 2022;30:889-898.

9. Guan WJ, Liang WH, He JX, Zhong NS. Cardiovascular comorbidity and its impact on patients with COVID-19. Eur Respir J. 2020;55(6):1069-1076.

10. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020;92(10):1902-1914. Available from: https://pubmed.ncbi.nlm.nih.gov/32293716/

11. Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in COVID-19 patients outside Wuhan, China: Retrospective case series. BMJ. 2020;368. Available from: https://pubmed.ncbi.nlm.nih.gov/32075786/

12. Huang S, Wang J, Liu F, Liu J, Cao G, Yang C, et al. COVID-19 patients with hypertension have more severe disease. Hypertens Res. 2020;43(8):824-831. Available from: https://doi.org/10.1038/s41440-020-0485-2

13. Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients. J Infect. 2020;80(6):e14-e18. Available from: https://pubmed.ncbi.nlm.nih.gov/32171866/

14. Husada JP, Saputra YE, Prahasanti K, Laitupa AA, Irawati DN. Gambaran faktor risiko lanjut usia terhadap kematian pasien COVID-19. Jurnal Pandu Husada. 2021;2(2):114-126. Available from: https://jurnal.umsu.ac.id/index.php/JPH/article/view/6402

15. Chen X, Hu MTW, Yang M, Ling J, Zhang Y, Deng L, et al. Risk factors for delayed viral clearance in COVID-19 patients. J Clin Hypertens. 2021;23(8):1483-1489. Available from: https://pubmed.ncbi.nlm.nih.gov/34171164/

16. Samrah SM, Al-Mistarehi AH, Kewan T, Al-Khatib SM, Ibnian AM, Samrah RS, et al. Viral clearance course of COVID-19 outbreaks. J Multidiscip Healthc. 2021;14:555-565. Available from: https://www.dovepress.com/viral-clearance-course-of-covid-19-outbreaks-peer-reviewed-fulltext-article-JMDH

17. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with COVID-19: Retrospective study.

18. Wang S, Zhang Q, Wang P, Ye H, Jing X, Zhang Z, et al. Clinical features of hypertensive patients with COVID-19 compared with normotensive group. Open Med. 2021;16(1):367. Available from: https://pmc/articles/PMC8024550/

19. O’Brien J, Du KY, Peng C. Incidence, clinical features, and outcomes of COVID-19 in Canada. Available from: https://doi.org/10.1186/s13048-020-00734-4

20. Goodman KE, Magder LS, Baghdadi JD, Pineles L, Levine AR, Perencevich EN, et al. Impact of sex and metabolic comorbidities on COVID-19 mortality risk across age groups. Clin Infect Dis. 2021;73(11):E4113-E4123.

21. Choi HM, Kim HC, Kang DR. Sex differences in hypertension prevalence and control: Analysis of Korea NHANES 2010-2014. PLoS One. 2017;12(5):1-12.

22. Chen J, Jiang Q, Xia X, Liu K, Yu Z, Tao W, et al. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression. Aging Cell. 2020;19(7). Available from: https://pubmed.ncbi.nlm.nih.gov/32558150/

23. Karyono DR, Wicaksana AL. Current prevalence, characteristics, and comorbidities of COVID-19 patients in Indonesia. J Community Empowerment Health. 2020;3(2):77-84. Available from: https://jcoemph.id/index.php/jcoemph/article/view/60

24. Ge H, Wang X, Yuan X, Xiao G, Wang C, Deng T, et al. The epidemiology and clinical information about COVID-19. 2019. Available from: https://doi.org/10.1007/s10096-020-03874-z

25. Chopra H, Kasliwal R, Muruganathan A, Wali M, Ram CVS. COVID-19, hypertension, and cardiovascular disease. J Diabetol. 2020;11(2):57. Available from: https://journals.lww.com/jodb/fulltext/2020/11020/covid_19_hypertension_and_cardiovascular_disease.4.aspx

26. Lippi G, Wong J, Henry BM. Hypertension in COVID-19 patients: A pooled analysis. Pol Arch Intern Med. 2020;130(4):304-309. Available from: https://europepmc.org/article/med/32231171

27. Aslanbeigi F, Rahimi H, Malekipour A, Pahlevani H, Najafizadeh M, Ehteram H, et al. Association between hypertension and clinical outcomes in COVID-19 patients: A case-controlled study. Ann Med Surg. 2023;85(7):3258-3263. Available from: https://pubmed.ncbi.nlm.nih.gov/37427160/

28. Trump S, Lukassen S, Anker MS, Lorenz Chua R, Liebig J, Thürmann L, et al. Hypertension delays viral clearance and exacerbates airway hyperinflammation in COVID-19 patients. Nat Biotechnol. Available from: https://doi.org/10.1038/s41587-020-00796-1

29. Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19. Hypertens Res. 2020;43(10):1028-1046. Available from: https://pubmed.ncbi.nlm.nih.gov/32737423/

30. Zhou X, Zhu J, Xu T. Clinical characteristics of COVID-19 patients with hypertension on renin-angiotensin system inhibitors. Clin Exp Hypertens. 2020;656-660. Available from: https://www.tandfonline.com/doi/abs/10.1080/10641963.2020.1764018

Downloads

Published

2025-11-30

How to Cite

Anisa, D. S., Wisudanti, D. D., & Wulandari, P. (2025). The Relationship Between Hypertension and Mortality in COVID-19 Patients at Soedirman M. S. Wonogiri Hospital. WMJ (Warmadewa Medical Journal), 10(2), 80–87. https://doi.org/10.22225/wmj.10.2.12434.80-87

Issue

Vol. 10 No. 2 (2025): November

Section

Articles

License

Copyright (c) 2025 Devisda Shafiy Anisa, Desie Dwi Wisudanti, Pipiet Wulandari

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.